GH Research PLC
GHRS Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$18.07
KIRA · Stoqly’s AI analyst, in plain words
- GH Research PLC lost $48.3M in fiscal 2025.
- Free cash flow was −$43.7M in fiscal 2025, — of revenue.
- GH Research PLC has $246M more cash than debt.
Market cap
$1.1B
P/E
—
Revenue
—
Net income
−$48.3M
Free cash flow
−$43.7M
Operating margin
—
GH Research PLC in 30 seconds · fiscal 2025
Does it make a profit?
−$48.3M
No. It lost money last year.
How healthy are the accounts?
3 / 7
Weak. It passes 3 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What GH Research PLC does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 20-F · Mar 5, 2026
- Legal name
- GH Research PLC
- CIK
- 0001855129
GH Research PLC · GHRS
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Net income | −$9.2M | −$22.5M | −$35.6M | −$39.0M | −$48.3M |
| Diluted EPS | −$0.21 | −$0.43 | −$0.68 | −$0.75 | −$0.79 |
| Cash | |||||
| Cash from operations | −$15.3M | −$26.2M | −$33.3M | −$42.3M | −$43.6M |
| Capital expenditure | $0.1M | $0.1M | $0.1M | $0.0M | $0.1M |
| Free cash flow | −$15.4M | −$26.3M | −$33.4M | −$42.3M | −$43.7M |
| Share count change | 54.0% | 19.1% | 0.0% | 0.0% | 17.3% |
| Debt and strength | |||||
| Cash and short-term investments | $277M | $166M | $78.4M | $101M | $246M |
| Debt incl. finance leases | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Shareholders' equity | $277M | $250M | $219M | $179M | $280M |
| Current ratio | 101.8x | 37.1x | 24.5x | 17.2x | 34.1x |
| Interest coverage | −1,677.8x | — | −654.3x | −70.2x | −131.1x |
| Returns and quality | |||||
| Return on capital | −2,989.7% | −28.8% | −23.2% | −50.9% | −143.4% |
| Return on equity | −6.5% | −8.5% | −15.2% | −19.6% | −21.0% |
| Return on tangible equity | −3.3% | −9.0% | −16.3% | −21.8% | −17.3% |
| Piotroski F-score | — | 0 | 1 | 0 | 3 |
| Altman Z'' | 111.9 | 60.7 | 33.7 | 21.6 | 37.6 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
GH Research PLC · GHRS
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $18.07 a share, the company is worth $1.1B.
Source: SEC EDGAR XBRL filings (CIK 0001855129). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.